Effect of ivermectin on infection with gastro-intestinal nematodes in Sierra Leone.
Levels of intestinal nematode infections were assessed six months after a two year trial of ivermectin for efficacy against onchocerciasis had ended. In the trial the inhabitants of six villages in Sierra Leone were offered treatment with ivermectin or placebo at six monthly intervals for four rounds in total. Quantitative faecal egg counts were carried out on stool samples provided by 202 subjects, all of whom had received all four rounds of treatment, in two of the villages (Dodo and Mogibisi). These data were analysed by a novel procedure in which a 3-way ANOVA with negative binomial errors enabled village and host gender influences on the outcome of treatment to be identified. Necator americanus was the most common species showing an overall prevalence of 90% but a higher intensity in Mogibisi relative to Dodo, particularly among male subjects. Neither prevalence nor intensity of infection were altered in ivermectin-treated compared with placebo-treated subjects. Trichuris trichiura was the least common species with a prevalence of 15%. It was concluded that there was no significant protection from infection with this species among the ivermectin relative to the placebo-treated subjects. Ascaris lumbricoides, with an overall prevalence of 39%, was more common among female (50%) compared with male (27%) villagers. Prevalence was not significantly affected by ivermectin but the intensity of infection declined by 91.3% in Dodo whilst in Mogibisi intensity was only reduced by 14.6%.(ABSTRACT TRUNCATED AT 250 WORDS)
Behnke
J M
JM
Department of Life Science, University of Nottingham, University Park, UK.
Pritchard
D I
DI
Wakelin
D
D
Park
J R
JR
McNicholas
A M
AM
Gilbert
F S
FS
D000328:Adult; D000704:Analysis of Variance; D002648:Child; D003710:Demography; D004311:Double-Blind Method; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D009855:Onchocerciasis / Q000453:epidemiology / Q000517:prevention & control*; D010270:Parasite Egg Count; D010919:Placebos; D015995:Prevalence; D011336:Probability; D012737:Sex Factors; D012807:Sierra Leone / Q000453:epidemiology
D010919:Placebos; D007559:Ivermectin